Amarin rises on US FDA acceptance of fish oil pill NDA
This article was originally published in Scrip
Executive Summary
Amarin investors had something to be grateful about the day after the US celebrated its Thanksgiving holiday, with the US FDA accepting the Bedminster, New Jersey-based biotech's new drug application (NDA) for AMR101 as a treatment for patients with very high triglycerides of 500mg/dL or above.